DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment

 

 

Oncology Homepage

Survey finds most patients prefer annual mammograms Challenges the USPSTF's recommendations

Carestream Health now shipping MyVue Center Self-Service Kiosk Provides patients with access to imaging exam records quicker

MEVION S250i Proton Therapy System scores CE mark First European installation to be in Netherlands

Researchers develop CT system for imaging extremely small objects Generates high-resolution 3-D images

RaySearch enters boron neutron capture therapy field Will add BNCT as a radiotherapy modality through alliance with Neutron Therapeutics

Can theranostics be the key to completely curing colorectal cancer? Preclinical trials yield promising results

Varian to install ProBeam at Penn Medicine and new hospital in China The 'latest proof of growing worldwide interest' in proton therapy

At PTCOG, research points to a need for greater access to proton therapy Pediatric patients face delays in insurance coverage

Karen Horton John Hopkins names director of department of radiology and radiological science

Proton therapy trumps IMRT for prostate cancer: study Research points to higher survival rates and fewer complications

iCAD's Xoft Axxent balloon applicators

China approves iCAD Xoft Axxent balloon applicators for early-stage breast cancer treatment

par John Fischer , Staff Reporter
The China Food & Drug Administration (CFDA) has approved the use of iCAD’s Xoft Axxent balloon applicators for treating early-stage breast cancer.

Doctors and clinicians in China can now use the applicators, a component of the the Xoft Axxent Electronic Brachytherapy (eBx) System, to administer intraoperative radiation therapy (IORT) to the site of tumors during the lumpectomy for patients with stage one or two breast cancer as well as those with Ductal carcinoma in situ (DCIS) that has not yet progressed to the lymph nodes.

Story Continues Below Advertisement

qualiTEE - reliabiliTEE - repairabiliTEE - we guaranTEE

Bayer HealthCare Multi Vendor Service will repair your transducer with the same precision and care you provide to your patients. Now offering TotalREPAIR on 140 transducer models! Call us at 1-844-5100 or visit www.mvs.bayer.com to set up an order today.



“More and more women are searching for effective alternatives for the treatment of early stage breast cancer,” Daniel Arnoff, vice president of global sales at iCAD, told HCB News. “Many women cannot comply with the six to eight weeks of external beam radiation following their surgery. IORT is done at the time of surgery, allowing appropriately selected patients to complete their full course of radiation in one day.”

The Xoft System’s miniaturized x-ray source is inserted into an applicator as a channel for administering a single and exact, high-dose rate of low energy radiation treatment to the lumpectomy cavity. The applicator delivers the dose, targeting the cancer cells directly, so as to reduce exposure of healthy surrounding tissue to the radiation.

The applicators come in different sizes and shapes and can be filled with different volumes of saline to fit the contour of the cavity exactly and enable delivery of a more conformal dose of radiation. They also come in a sterile pack, eliminating the need for sterilization and decreasing the risk of cross-contamination.

Arnoff says the Xoft system and its applicators have the potential to become a standard option for treating breast cancer in China, and that with more research, could be used to treat other forms of cancer.

“As additional data emerge in support of other clinical applications, we expect that other countries, including China, will consider utilizing the Xoft System and its variety of applicators for a range of cancers,” he said.

The Xoft system and its applicators are FDA-approved and CE-marked to treat cancer in any part of the body, including early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.

Oncology Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2017 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS